Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is set to release its fourth quarter and full year 2022 financial results after market close on March 30, 2023. This announcement will be followed by a conference call at 5:00 PM ET to discuss the results and recent milestones. Vivos specializes in medical devices for treating sleep disorders, particularly obstructive sleep apnea (OSA) and snoring, through its proprietary oral appliances. The company has treated over 33,000 patients globally, showcasing the effectiveness of its noninvasive Vivos Method, developed by trained dentists. The company emphasizes its commitment to innovation in the sleep disorder treatment sector.
- Vivos has treated over 33,000 patients, indicating strong demand for its products.
- The Vivos Method offers a clinically effective, noninvasive solution for mild to moderate OSA.
- None.
Call Scheduled for Today, Thursday, March 30, 2023 at 5:00 pm ET
LITTLETOWN, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults, including mild-to-moderate obstructive sleep apnea (OSA) and snoring, today announced it plans to release its fourth quarter and full year 2022 financial results after market close today, Thursday, March 30, 2023. The Company will conduct a conference call today at 5:00 pm (Eastern Time) to review the results and provide an overview of the Company’s recent milestones and developments.
To access the conference call, please dial (877) 451-6152, or for international callers, (201) 389-0879. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live call and the replay is 13737313. The replay will be available until April 13, 2023.
A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online archive of the webcast will be available on the Company’s website for 30 days following the call.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing related sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in over 33,000 patients treated worldwide by more than 1,700 trained dentists.
The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including, without limitation, the results of the Company’s acquisition, sales, marketing, research and development and regulatory initiatives) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Vivos Investor Relations Contact:
Julie Gannon
Investor Relations Officer
720-442-8113
jgannon@vivoslife.com
FAQ
When will Vivos Therapeutics release its 2022 financial results?
What are the main products offered by Vivos Therapeutics?
How effective is the Vivos Method in treating sleep disorders?
What time is the Vivos Therapeutics conference call scheduled?
How can I access the Vivos Therapeutics conference call?
